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Hyperglycaemia has been observed with exposure to organophosphate insecticides. This study was 
designed to compare the effects of calcium channel blockers, alpha-adrenergic, beta-adrenergic, and 
muscarinic receptor blockers, and of free radical scavengers on insulin secretion from diazinon-treated 
islets of Langerhans isolated from the pancreas of rats using standard collagenase digestion, separation by 
centrifugation, and hand-picking technique. The islets were then cultured in an incubator at 37 °C and 5 % 
CO
2
. In each experimental set 1 mL of 8 mmol L-1 glucose plus 125 µg mL-1 or 625 µg mL-1 of diazinon 
were added, except for the control group, which received 8 mmol L-1 glucose alone. The cultures were then 
treated with one of the following: 30 µmol L-1 atropine, 100 µmol L-1 ACh + 10 µmol L-1 neostigmine, 
0.1 µmol L-1 propranolol, 2 µmol L-1 nifedipine, 50 µmol L-1 phenoxybenzamine, or 10 µmol L-1 alpha-
tocopherol. In all experiments, diazinon signifi cantly reduced glucose-stimulated insulin secretion at both 
doses, showing no dose dependency, as the average inhibition for the lower dose was 62.20 % and for the 
higher dose 64.38 %. Acetylcholine and alpha-tocopherol restored, whereas atropine potentiated diazinon-
induced hyposecretion of insulin. Alpha-, beta- and calcium channel blockers did not change diazinon-
induced effects. These fi ndings suggest that diazinon affects insulin secretion mainly by disturbing the 
balance between free radicals and antioxidants in the islets of Langerhans and by inducing toxic stress.
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Diazinon {O,O-diethyl-O-[6-methyl-2- (1-
methylethyl)-4pyrimidinyl] phosphorothioate} is 
a widely used organophosphorus (OP) insecticide. 
It may pollute the environment, enter the food 
cycle, and cause chronic toxic effects in humans. 
The main mechanism of OP action is to inhibit 
acetylcholinesterase (AChE) activity in target tissue 
(1). Poisoning with OPs is a major health concern that 
has not been resolved (2-7). In addition to cholinergic 
effects usually observed with OPs, Rahimi and 
Abdollahi (8) singled out hyperglycaemia as one of 
the consequences of both acute and chronic exposure 
to OPs. Among different mechanisms that have been 
suggested for OP-induced hyperglycaemia, effects 
on pancreatic islets have received much attention in 
recent years. Research on islets of Langerhans isolated 
from rats pre-treated subchronically with malathion 
has indicated that insulin secretion is inhibited in the 
presence of basal and stimulatory concentrations of 
glucose (9-11).
Our earlier studies have shown that subchronic 
exposure of rats to malathion increased both blood 
glucose and insulin and muscle phosphofructokinase 
and glycogen phosphorylase (GP) activities, resulting 
with increased glycogenolysis and glycolysis (12). 
It has also been found that malathion stimulates GP 
and phosphoenolpyruvate carboxykinase (PEPCK) 
activities in the liver (13). On the other hand, there 
is evidence that glycogen may be stored in the liver 
due to higher insulin secretion after the inhibition of 
AChE activity in pancreatic B-cells by subchronic 
administration of malathion (14). In addition, 
administration of diazinon to rats increased serum 
glucose and decreased glycogen content in the 
brain while glycogenolytic activities of glycogen 
phosphorylase and phosphoglucomutase increased 
signifi cantly (15).
Furthermore, antioxidants like alpha-tocopherol 
and N-acetylcysteine (NAC) have shown a protective 
role against OP-induced glucose changes (6, 
16). There is also evidence that the effi ciency of 
phosphodiesterase inhibitors in countering diazinon-
induced hyperglycaemia depends on their antioxidant 
potential  (17, 18).
Insulin secretion from the islets of Langerhans 
is infl uenced by muscarinic cholinergic and then 
adrenergic systems. Calcium channels are also 
involved in mediating the effects of neurotransmitters 
(19). This study was designed to compare the effects 
of calcium channel blockers, alpha-adrenergic, beta-
adrenergic, and muscarinic receptor blockers, and free 
radical scavengers on insulin secretion from isolated 
rat islets of Langerhans in the presence of diazinon.
MATERIALS AND METHODS
Chemicals
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, HCl, bovine serum albumin 
(BSA), alpha-tocopherol (Trolox®), acetylcholine, 
neostigmine, and diazinon were purchased from 
Sigma-Aldrich Co. (Dorset, England). RPMI medium 
and its supplements were purchased from Invitrogen 
Co. (Gibco, UK). Rat insulin ELISA kit was purchased 
from Mercodia Co. (Uppsala, Sweden). Propranolol, 
nifedipine, phenoxybenzamine, and atropine were 
obtained from local pharmaceutical companies.
Animals
Male Wistar rats weighing 200 g to 250 g were 
housed in polypropylene cages under standard 
conditions with free access to drinking water and 
food, 12-h light : 12-h dark cycle, and an ambient 
temperature of (20 to 25) °C. All experiments were 
performed according to the Animal Welfare Act, 
and the study protocol was approved by the ethics 
committee of the Pharmaceutical Sciences Research 
Center, Tehran University of Medical Sciences.
Islet isolation and culture
Rats were anaesthetised with intraperitoneal 
injection of sodium pentobarbital (60 mg kg-1) and 
underwent laparatomy; the common bile duct was 
ligated at its exit into the liver. The duct was then 
cannulated at its exit from the duodenum. Then 
the pancreas was distended by injecting 10 mL of 
cold collagenase V (1 mg mL-1) prepared in Hanks-
















, 0.35 g L-1 NaHCO
3
, 2.32 g L-1 Hepes, 0.4 g L-1 
glucose⋅H
2




O, pH 7.2). After 
perfusion, the islets were kept in Krebs buffer (8 g L-1 
NaCl, 0.27 g L-1 KCl, 0.42 g L-1 NaHCO
3





, 0.05 g L-1 MgCl
2
, 2.38 g L-1 HEPES, 




O, 0.5 g L-1 glucose⋅H
2
O, pH 7.4), 
centrifuged, separated from the remaining tissue by 
hand-picking under a stereomicroscope, and incubated 
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Figure 1  Insulin release from islets of Langerhans incubated for 
30 min in the presence 8 mmol L-1 glucose as control 
(Con) plus diazinon (D) alone or in combination with 
acetylcholine (Ac) and neostigmine (Ne). 
Diazinon alone at doses of 125 µg mL-1 and 
625 µg mL-1, 100 µmol L-1 acetylcholine and 
10 µmol L-1 neostigmine alone, or diazinon in 
combination with 100 µmol L-1 acetylcholine and 
10 µmol L-1 neostigmine were used. Values are 
means±SEM. a P<0.05 for difference from control, 
b P<0.05 for difference from diazinon alone at doses 
of 125 µg mL-1 and 625 µg mL-1.
Figure 2  Insulin release from islets of Langerhans incubated 
for 30 min in the presence 8 mmol L-1 glucose 
as control (Con) plus diazinon (D) alone or in 
combination with atropin (At). 
Diazinon alone at doses of 125 µg mL-1 and 
625 µg mL-1, 30 mmol L-1 atropine alone, or diazinon 
in combination with 30 mmol L-1 atropine were used. 
Values are means±SEM. a P<0.05 for difference 
from control.
Figure 3  Insulin release from islets of Langerhans incubated for 
30 min in the presence 8 mmol L-1 glucose as control 
(Con) plus diazinon (D) alone or in combination with 
alpha-tocopherol (VE). Diazinon alone at doses of 
125 µg mL-1 and 625 µg mL-1, 10 µmol L-1 alpha-
tocopherol alone, or diazinon in combination with 
10 µmol L-1  alpha-tocopherol were used. Values are 
means±SEM. a P<0.05 for difference from control, b 
P<0.05 for difference from diazinon alone at doses 
of 125 µg mL-1 and 625 µg mL-1.
Figure 4  Insulin release from islets of Langerhans incubated 
for 30 min in the presence 8 mmol L-1 glucose 
as control (Con) plus diazinon (D) alone or in 
combination with nifedipine (Nf).
Diazinon alone at doses of 125 µg mL-1 and 
625 µg mL-1, 2 µmol L-1 nifedipine alone, or diazinon 
in combination with 2 µmol L-1 nifedipine were used. 
Values are means±SEM. a P<0.05 for difference from 
control, b P<0.05 for difference from diazinon alone 
at doses of 125 µg mL-1 and 625 µg mL-1.
overnight in a supplemented RPMI-1640 medium 
containing 10 % BSA, 1 % penicillin-streptomycin, and 
0.1 % gentamycin at  5 % CO
2
 and 37 °C (10).
Static insulin secretion
The islets were washed in Krebs-Ringer buffer 
and then pre-incubated for 30 min in a water bath 
with the same buffer at 37 °C. The islets were 
washed again and then dispensed in batches of 10 
using a stereomicroscope. In each experimental set 
1 mL of 8 mmol L-1 glucose plus 125 µg mL-1 or 
625 µg mL-1 of diazinon were added except for the 
control group, which was treated with 8 mmol L-1 
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with one of the following solutions: 30 µmol L-1 
atropine, 100 µmol L-1 ACh+10 µmol L-1 neostigmine, 
0.1 µmol L-1 propranolol, 2 µmol L-1 nifedipine, 
50 µmol L-1 phenoxybenzamine, or 10 µmol L-1 alpha-
tocopherol. The low and the high dose of diazinon 
were around 1/10 and 1/3 of its LD
50
, respectively (9-
11). ACh degradation was prevented by neostigmine, 
as it inhibits AChE activity.
The islets were incubated for 30 minutes in a 
water bath (at 37ºC), tubes were placed on ice, and 
the supernatant was taken to measure secreted insulin 
using the ELISA method (10).
Statistical analysis
Data were expressed as means ± SEM of separated 
experiments and analysed using one-way ANOVA 
followed by Dunnett post hoc multiple comparison 
tests. The signifi cance level was set at P<0.05.
RESULTS
Glucose-stimulated insulin secretion
In all experiments, either dose of diazinon 
signifi cantly (P<0.05) reduced glucose-stimulated 
insulin secretion. The average inhibition was 62.20 % at 
125 µg mL-1 and 64.38 % at 625 µg mL-1, and showed 
no dose-dependence (Figures 1-6). ACh+neostigmine 
with 125 µg mL-1 diazinon increased glucose-
stimulated insulin secretion 64.4 % in comparison 
with diazinon given alone while ACh+neostigmine 
with 625 µg mL-1 diazinon increased it 95.5 % 
in comparison with diazinon given alone (Figure 
1). Atropine alone decreased glucose-stimulated 
insulin secretion to 13.98 % of control. Atropine 
plus diazinon at either dose further reduced insulin 
secretion compared to diazinon alone (Figure 
2). Alpha-tocopherol plus 125 µg mL-1 diazinon 
increased glucose-stimulated insulin secretion 54 % 
in comparison with diazinon given alone while alpha-
tocopherol plus 625 µg mL-1 diazinon increased it 
134 % in comparison with diazinon given alone 
(Figure 3). Nifedipine decreased glucose-stimulated 
insulin secretion to 21.4 % of control. Nifedipine plus 
diazinon did not alter insulin secretion in comparison 
with diazinon alone (Figure 4). Phenoxybenzamine 
plus diazinon did not alter insulin secretion in 
comparison with diazinon alone (Figure 5).
Propranolol decreased glucose-stimulated insulin 
secretion to 21.7 % of control. Propranolol plus 
diazinon did not alter insulin secretion in comparison 
with diazinon alone (Figure 6).
DISCUSSION
The results of this study have shown that diazinon 
significantly reduces glucose-stimulated insulin 
secretion in a manner that is not dose-dependent 
(62.20 % inhibition at 125 µg mL-1 and 64.38 % 
at 625 µg mL-1). Among the blockers tested, only 
Figure 6  Insulin release from islets of Langerhans incubated 
for 30 min in the presence 8 mmol L-1 glucose as 
control (Con) plus diazinon alone or in combination 
with propranolol (Pr).
Diazinon alone at doses of 125 µg mL-1 and 625
µg mL-1, 0.1 µmol L-1 propranolol alone, or diazinon 
in combination with 0.1 µmol L-1  propranolol were 
used. Values are means±SEM of 3 experiments. 
a P<0.05 for difference from control.
Figure 5  Insulin release from islets of Langerhans incubated 
for 30 min in the presence 8 mmol L-1 glucose 
as control (Con) plus diazinon (D) alone or in 
combination with phenoxybenzamine (Ph).
Diazinon alone at doses of 125 µg mL-1 and 625
µg mL-1, 50 µmol L-1 phenoxybenzamine alone, 
or diazinon in combination with 50 µmol L-1 
phenoxybenzamine were used. Values are 
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atropine potentiated diazinon-induced hyposecretion 
of insulin. Antioxidant alpha-tocopherol showed the 
same protection level like ACh. Our results confi rm 
that diazinon acts both through the cholinergic system 
and free radical-induced stress. The controlling role 
of the cholinergic system in insulin release has been 
proposed by studies in mice (20), rats (21), monkeys 
(22), and humans (23). ACh is believed to be a potent 
secretagogue of both insulin and glucagon while the 
autonomic nervous system affects glucose-dependent 
insulin secretion (24, 25). There is evidence that 
carbachol, a cholinergic agonist, increases glucose-
induced insulin secretion from isolated rat islets (26), 
which corresponds to our results showing that ACh can 
recover diazinon-induced drop in insulin secretion. In 
all our experiments, insulin secretion was stimulated 
by 8 mmol L-1 glucose to better track changes caused 
by interactive compounds. In these conditions, 
addition of stimulants like ACh does not increase 
insulin secretion over control, because it has already 
reached the highest possible secretory level. In beta-
cells, ACh is thought to bind to muscarinic M3 receptor 
subtype and to exert complex effects eventually 
leading to increased insulin secretion. Activation 
of phospholipase C (PLC) generates diacylglycerol 
(DAG) that activates protein kinase C (PKC), thereby 
increasing the effi ciency of free cytosolic calcium 
concentration on exocytosis of insulin granules. ACh 
activates intracellular movement of secretory granules 
as a result of muscarinic mobilization of intracellular 
calcium (27). Inositol-3-phosphate (IP3) produced by 
PLC causes a rapid elevation of calcium by mobilising 
calcium from the endoplasmic reticulum. The resulting 
fall in calcium in the organelle produces a small 
capacitative calcium entry (25). Atropine, an agent 
that blocks muscarinic receptors, decreased glucose-
induced insulin release. It has been reported that the 
inhibitory effect of clozapine (which strongly binds to 
muscarinic M3 receptor) or atropine is not observed 
under non-stimulatory glucose concentration, but is 
evident at 7.0 mmol L-1 glucose (28). Confi rming the 
role of ACh, our data indicate that atropine reduced 
8 mmol L-1 glucose-stimulated insulin secretion 
when used alone, but, interestingly, it potentiated 
the diazinon-induced effect (Figure 2). In addition, 
the inhibitory effect of diazinon is partly diminished 
by ACh. This confi rms the controversy between the 
proposed mechanisms of OP-induced changes in 
hormonal glucose control by pancreas and also non-
hormonal changes by organs such as liver or muscles 
(11, 24, 30-38). The cholinergic system seems to 
be responding well to ACh and atropine, which 
suggests that the method used is reliable, but diazinon 
most probably works by a mechanism other than 
cholinergic. In fact, in this in vitro model, this kind 
of interaction between diazinon and the cholinergic 
system is not too surprising because the amount of 
cholinesterase in the islets seems to be insuffi cient, 
and therefore the effects observed here are possibly 
mediated only by diazinon and not by ACh.
Our data also showed that even though 
phenoxybenzamine, propranolol, and nifedipine, 
inhibited glucose-induced insulin release, they could 
not change diazinon-induced insulin reduction. The 
reduction of glucose-stimulated insulin confi rms the 
effi ciency of the selected blockers and, again, the 
reliability and reproducibility of this in vitro model. 
It turns out that the adrenergic system and calcium 
channels do not have the main role in diazinon-induced 
changes.
Our experiment with alpha-tocopherol sheds more 
light on the effects of diazinon in the presence of ACh 
and atropine. OPs are known to produce oxidative 
stress by generating free radicals and modifying the 
antioxidant defence system. Many studies have already 
indicated that enzymes associated with antioxidant 
defence mechanisms are altered under the infl uence of 
OPs, and that lipid peroxidation is one of the molecular 
mechanisms involved in OP-induced cytotoxicity (8, 
11, 13, 29-31, 35-38). Further supportive evidence 
comes from studies indicating diazinon-induced free 
radical damage to pancreatic B-cells as the cause of 
hyperglycaemia in animals (17, 30). Our study has 
shown that alpha-tocopherol is a potent antioxidant 
that can restore diazinon-reduced insulin secretion, 
most probably by preventing free radical toxic 
damage. This is supported by a report on increased 
glucose-stimulated insulin release one day after 
exposure of islets to alpha-tocopherol (39). In addition, 
pre-incubation of pancreatic islet cells with alpha-
tocopherol signifi cantly improved their resistance to 
toxic doses of nitric oxide (40). A recent study (41) 
has shown that when diazinon was administered in vivo 
at doses of (15 to 60) mg kg-1 to rats, plasma insulin 
decreased while C-peptide concentrations increased. In 
addition, diazinon increased the activity of glutamate 
dehydrogenase (GDH), decreasing at the same time 
the expression of GDH gene. This suggests that GDH 
participates in diazinon-induced changes in the release 
of immature insulin. Therefore, it is reasonable to 
conclude that diazinon induces secretion of immature 
insulin from isolated islets.
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Our results and the above-mentioned evidence 
suggest that diazinon can affect insulin secretion 
mainly by disturbing the balance between free radicals 
and antioxidants in the islets of Langerhans and by 
inducing toxic stress and release of immature insulin. 
A number of evidence on the relationship between 
oxidative stress and diabetes (32-34, 42-47) even by 
OP compounds (48) supports this conclusion, and 
calls for further research of the benefi cial effects of 
antioxidants (49). Our future work will focus on the 
balance between insulin secretion, antioxidant levels, 
and islet cytotoxicity.
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Sažetak
USPOREDBA DJELOVANJA BLOKATORA KALCIJEVIH KANALA, BLOKATORA 
AUTONOMNOGA ŽIVČANOG SUSTAVA TE INHIBITORA SLOBODNIH RADIKALA NA 
HIPOSEKRECIJU INZULINA IZ IZOLIRANIH LANGERHANSOVIH OTOČIĆA ŠTAKORA 
UZROKOVANU DIAZINONOM
U osoba izloženih organofosfatnim insekticidima zamijećen je nastanak hiperglikemije. Svrha je ovog 
istraživanja bila usporediti djelovanje blokatora kalcijevih kanala, alfa i beta-adrenergičkih i muskarinskih 
receptora te inhibicije slobodnih radikala na lučenje inzulina iz Langerhansovih otočića izoliranih iz štakora 
tretiranih diazinonom.
Otočići su izolirani iz gušterače štakora s pomoću standardnog postupka digestije kolagenazom, odvajanja 
centrifugiranjem i metodom ručnog probira (engl. hand-picking) te su kultivirani u inkubatoru pri 37 °C 
i 5 % CO
2
. Pokusne su kulture inkubirane s 1 mL glukoze u koncentraciji od 8 mmol L-1 te diazinonom u 
dozi od 125 µg mL-1, odnosno 625 µg mL-1. U kontrolu je dodana samo glukoza u koncentraciji od 8 mmol
L-1. Nakon toga je u kulture dodan jedan od sljedećih agenasa: 30 µmol L-1 atropin, 100 µmol L-1 ACh + 
10 µmol L-1 neostigmin, 0,1 µmol L-1 propranolol, 2 µmol L-1 nifedipin, 50 µmol L-1 fenoksibenzamin, 
odnosno 10 µmol L-1 alfa-tokoferol. U svim je pokusima diazinon značajno smanjio lučenje inzulina, s 
time da je doza od 125 µg mL-1 dovela do 62,2%-tne inhibicije, a doza od 625 µg mL-1 do 64,38%-tne 
inhibicije lučenja inzulina, što upućuje na djelovanje neovisno o dozi. Acetilkolin i alfa-tokoferol su 
ponovno potaknuli lučenje inzulina, za razliku od atropina koji ga je dodatno smanjio. Primjena blokatora 
alfa i beta-adrenergičkih receptora te blokatora kalcijevih kanala nije utjecala na djelovanje diazinona. 
Autori zaključuju da diazinon utječe na lučenje inzulina ponajviše narušavanjem ravnoteže između slobodnih 
radikala i antioksidansa u Langerhansovim otočićima te dovodi do toksičnoga stresa.
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